Literature DB >> 26335862

Interim results from a phase 3 Ebola vaccine study in Guinea.

Philip R Krause1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26335862     DOI： 10.1016/S0140-6736(15)00002-1

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  10 in total

1.  Ebola vaccine trial falls short of homerun.

Authors:  Laura DeFrancesco
Journal:  Nat Biotechnol       Date:  2015-10       Impact factor: 54.908

2.  Considerations for Use of Investigational Drugs in Public Health Emergencies.

Authors:  Matthew Carl Kirchoff; Jerome F Pierson
Journal:  Ther Innov Regul Sci       Date:  2016-01-01       Impact factor: 1.778

3.  Human antibody repertoire after VSV-Ebola vaccination identifies novel targets and virus-neutralizing IgM antibodies.

Authors:  Surender Khurana; Sandra Fuentes; Elizabeth M Coyle; Supriya Ravichandran; Richard T Davey; John H Beigel
Journal:  Nat Med       Date:  2016-10-31       Impact factor: 53.440

4.  Longitudinal Human Antibody Repertoire against Complete Viral Proteome from Ebola Virus Survivor Reveals Protective Sites for Vaccine Design.

Authors:  Surender Khurana; Supriya Ravichandran; Megan Hahn; Elizabeth M Coyle; Spencer W Stonier; Samantha E Zak; Jason Kindrachuk; Richard T Davey; John M Dye; Daniel S Chertow
Journal:  Cell Host Microbe       Date:  2020-02-12       Impact factor: 21.023

5.  Ethical Rationale for the Ebola "Ring Vaccination" Trial Design.

Authors:  Annette Rid; Franklin G Miller
Journal:  Am J Public Health       Date:  2016-01-21       Impact factor: 9.308

Review 6.  Post-exposure prophylactic vaccine candidates for the treatment of human Risk Group 4 pathogen infections.

Authors:  James Logue; Ian Crozier; Peter B Jahrling; Jens H Kuhn
Journal:  Expert Rev Vaccines       Date:  2020-01-30       Impact factor: 5.683

7.  Next Steps for Ebola Vaccination: Deployment in Non-Epidemic, High-Risk Settings.

Authors:  Laura A Skrip; Alison P Galvani
Journal:  PLoS Negl Trop Dis       Date:  2016-08-18

8.  Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!).

Authors:  Ana Maria Henao-Restrepo; Anton Camacho; Ira M Longini; Conall H Watson; W John Edmunds; Matthias Egger; Miles W Carroll; Natalie E Dean; Ibrahima Diatta; Moussa Doumbia; Bertrand Draguez; Sophie Duraffour; Godwin Enwere; Rebecca Grais; Stephan Gunther; Pierre-Stéphane Gsell; Stefanie Hossmann; Sara Viksmoen Watle; Mandy Kader Kondé; Sakoba Kéïta; Souleymane Kone; Eewa Kuisma; Myron M Levine; Sema Mandal; Thomas Mauget; Gunnstein Norheim; Ximena Riveros; Aboubacar Soumah; Sven Trelle; Andrea S Vicari; John-Arne Røttingen; Marie-Paule Kieny
Journal:  Lancet       Date:  2016-12-23       Impact factor: 79.321

9.  How can health systems be strengthened to control and prevent an Ebola outbreak? A narrative review.

Authors:  Krishna Regmi; Ruth Gilbert; Colin Thunhurst
Journal:  Infect Ecol Epidemiol       Date:  2015-11-24

10.  Human Antibody Repertoire following Ebola Virus Infection and Vaccination.

Authors:  Sandra Fuentes; Supriya Ravichandran; Elizabeth M Coyle; Laura Klenow; Surender Khurana
Journal:  iScience       Date:  2020-02-19
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.